#monoclonalantibody — Public Fediverse posts

Sterile Liquid Filters Market in Denmark | Report – IndexBox

This report is a…
#Denmark #Danmark #DK #Europe #Europa #EU #AsymmetricPES(Polyethersulfone)membranes #biopharmamarketreport #denmark #forecast #gamma-irradiatedassemblies #GeneTherapyViralVectorPurification #HollowfiberTFF #MarketAnalysis #MonoclonalAntibody(mAb)Purification #Pre-packed #RecombinantProteinFinalFill #sterileliquidfilters #VaccineDownstreamProcessing #Virus-retentiveparvovirusfilters
https://www.europesays.com/2891182/

**VNVC bắt đầu tiêm kháng thể đơn dòng phòng RSV cho trẻ từ ngày 23/12. Dịch vụ triển khai tại 250+ trung tâm trên cả nước, giúp bảo vệ trẻ sơ sinh & nhũ nhi trước nguy cơ viêm phổi, viêm tiểu phế quản trong mùa dịch hô hấp cao điểm.**

#VNVC #SứcKhỏeTrẻEm #PhòngBệnh #RSV
#Healthcare #ChildHealth #RSVPrevention #MonoclonalAntibody

https://vietnamnet.vn/vnvc-trien-khai-tiem-khang-the-don-dong-phong-rsv-cho-tre-nho-2475397.html

https://www.europesays.com/ie/217283/ Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer #Antibody #blood #BloodVessels #BreastCancer #cancer #Cell #CellDeath #chemotherapy #Doxorubicin #Éire #Health #Hormone #IE #ImmuneSystem #Interferon #InterferonGamma #Ireland #Lungs #Metastasis #MonoclonalAntibody #Preclinical #Protein #Research #Surgery #Therapeutics #therapy #Tumor #TumorAssociatedMacrophages

Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Team

https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/

Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Team

https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/

Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Team

https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/

Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Team

https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/

Hympavzi (marstacimab): New Treatment for Hemophilia
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval...........
#bleedingdisorder #HemophiaB #Hemophilia #HemophiliaA #Hympavzi #marstacimab #Monoclonalantibody
SCIEU Team

https://www.scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/

Lecanemab for Early Alzheimer’s Disease approved in the UK but refused in EU 
Monoclonal antibodies (mAbs) lecanemab and donanemab have been approved forthe treatment of early Alzheimer’s disease in the UK and USA respectively...........
#Alzheimer’sDisease #Dementia #EarlyAlzheimer’sDisease #EU #Lecanemab #Monoclonalantibody #onanemab #UK #usa
Umesh Prasad

https://www.scientificeuropean.co.uk/medicine/lecanemab-for-early-alzheimers-disease-approved-in-the-uk-but-refused-in-eu/

https://www.abc.net.au/news/2024-03-25/qld-rsv-jab-explainer-who-is-eligible/103630628?utm_source=abc_news_app&utm_medium=content_shared&utm_campaign=abc_news_app&utm_content=other “The state government has announced a $31 million program to immunise more than 70,000 newborn babies, eligible infants and young children.

They will be given a #MonoclonalAntibody – or man-made protein – called Nirsevimab, which is marketed as Beyfortus.

Delivered as an injection, #Nirsevimab has been shown to be about 80 per cent effective at preventing young infants from being hospitalised with lower respiratory tract infection, caused by #RSV.”

A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers.

https://sciencebusiness.technewslit.com/?p=45299

#News #Press #Science #Business #Biotechnology #Chemistry #Engineering #Proteins #Antibody #Antigens #MonoclonalAntibody #GeneticEngineering #NIH #Grant #SBIR

'Coinciding with rising awareness about the risks of R.S.V., there are finally tools available to prevent severe infections in both infants and older adults.'
#Infection #immunology #vaccines #MonoclonalAntibody #RSV

https://www.nytimes.com/article/rsv-vaccine.html

Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

#Wegovy #Mounjaro #ozempic #weightloss
https://bioprocessintl.com/bioprocess-insider/deal-making/lilly-going-bigger-on-obesity-with-versanis-buy/

Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

#Wegovy #Mounjaro #ozempic #weightloss
https://bioprocessintl.com/bioprocess-insider/deal-making/lilly-going-bigger-on-obesity-with-versanis-buy/

Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

#Wegovy #Mounjaro #ozempic #weightloss
https://bioprocessintl.com/bioprocess-insider/deal-making/lilly-going-bigger-on-obesity-with-versanis-buy/

Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

#Wegovy #Mounjaro #ozempic #weightloss
https://bioprocessintl.com/bioprocess-insider/deal-making/lilly-going-bigger-on-obesity-with-versanis-buy/

Expect a renewed big push for obesity treatments. Lots of money riding on these therapies!

Eli #Lilly will pay up to $1.9 billion to acquire biotech #Versanis for it’s Phase II #Obesity candidate #Bimagrumab, a #MonoclonalAntibody that binds activin type II A and B receptors to block activin and myostatin signaling. The candidate is in Phase II trials both as a standalone drug and in combination with the anti-#diabetes peptide #semaglutide.

#Wegovy #Mounjaro #ozempic #weightloss
https://bioprocessintl.com/bioprocess-insider/deal-making/lilly-going-bigger-on-obesity-with-versanis-buy/

Less is more for monoclonal antibody affinity?
(Particularly if deletion is not the goal)

"This approach delivered higher immune cell activation, in vivo T cell expansion and antitumour activity in the case of CD40. Moreover, an inert anti-4-1BB monoclonal antibody was transformed into an agonist. Low-affinity variants of the clinically important antagonistic anti-PD-1 monoclonal antibody nivolumab also mediated more potent signalling and affected T cell activation."

#Monoclonal #MonoclonalAntibody #immunology #drugdiscovery #drugdevelopment

https://www.nature.com/articles/s41586-022-05673-2

My latest Clinical Pipeline column for #NatureMedicine is out, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.
#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-023-00017-7

My latest Clinical Pipeline column for #NatureMedicine is out today, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.

#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-023-00017-7

"The strong dependence on T cells in MS animal models (experimental autoimmune encephalomyelitis, EAE) and the absence of antibodies in MS have long driven the assumption of MS being orchestrated by T helper cells (12), making those the most plausible therapeutic targets. But anti-CD20 therapies have been a game changer in the MS field."

#Immunology #MultipleSclerosis #MonoclonalAntibody #Autoimmunity

https://www.pnas.org/doi/10.1073/pnas.2221544120

You'll never guess what happened next...

"The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000-a-year list price."

#TNF #RheumatoidArthritis #lupus #PublicHealth #Humira #MonoclonalAntibody

https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html

My latest clinical pipeline column for @NatureMedicine is out today.
It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody
for relapsed or refractory follicular #lymphoma.

#FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment

https://www.nature.com/articles/d41591-023-00010-0

"Using novel humanized IBC mouse models, we discovered that EGFR-targeted therapy remodels the IBC TME by increasing cytotoxic T cells and reducing immunosuppressive regulatory T cells and M2 macrophages. These changes were due to diminishing immunosuppressive chemokine expression regulated by transcription factor EGR1. We also showed that induction of an immunoactive IBC TME by an anti-EGFR antibody improved the antitumor efficacy of an anti–PD-L1 antibody."

#Immunology #Immunotherapy #EGFR #DrugDevelopment #MonoclonalAntibody

https://www.science.org/doi/10.1126/sciadv.abn7983

"The 18-month investigation, initiated by two congressional committees after the F.D.A. approved the drug, also strongly criticized Biogen, Aduhelm’s manufacturer. Internal documents showed the company set “an unjustifiably high price” of $56,000 a year for Aduhelm because it wanted a history-making “blockbuster” to “establish Aduhelm as one of the top pharmaceutical launches of all time,” even though it knew the high price would burden Medicare and patients, the report found."

#Aduhelm #MonoclonalAntibody #Alzheimer #AlzheimersDisease #Aducanumab

https://www.nytimes.com/2022/12/29/health/alzheimers-drug-aduhelm-biogen.html?action=click&module=Well&pgtype=Homepage&section=Health

Here's the fulcrum of this story, the paper where the Bluestone group and collaborators turn the mouse anti-human CD3 monoclonal into a chimeric, non-Fc activating molecule: Alegre et al, 1994

#MonoclonalAntibody #MolecularBiology #AntibodyEnginering #DrugDiscovery #DrugDevelopment #NatureMedicine #Diabetes #Type1Diabetes #Immunotherapy

https://pubmed.ncbi.nlm.nih.gov/8009586/

My latest clinical pipeline column for Nature Medicine is a look at a drug recently approved by the #FDA to delay the onset of type 1 diabetes.

It's a direct descendant of the very first monoclonal ever approved for clinical use.

#Diabetes #Type1Diabetes #DrugDevelopment #DrugDiscovery #NatureMedicine #Immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-022-00115-y

'We use data on changes in the in vivo concentration of monoclonal antibodies, and the associated protection from COVID-19, over time to model the dose-response relationship of monoclonal antibodies for prophylaxis. We estimate that 50% protection from COVID-19 is achieved with a monoclonal antibody concentration of 939-fold of the in vitro IC50 (95% CI: 135 - 2073).'

#Preprint #MonoclonalAntibody #Covid#Covid19

https://www.medrxiv.org/content/10.1101/2022.11.22.22282199v1

Not good news on the clinically available monoclonals vs newer covid lineages.

"Our data reveal that emerging omicron sublineages are resistant to most (ie, BA.4.6, BA.2.75.2, and BJ.1) or all (BQ.1.1) clinically used mAbs. As a consequence, in patients at high risk, treatment with mAbs alone might not provide a therapeutic benefit in regions of the globe in which BQ.1.1 is spreading, suggesting that additional treatment options (eg, paxlovid or molnupiravir) should be considered. Furthermore, novel, broadly active mAbs are urgently needed for prophylactic or therapeutic treatment, or both, in patients at high risk."

#COVID #Antibody #MonoclonalAntibody

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00733-2/fulltext

Monoclonal targeting Plasmodium falciparum circumsporozoite protein (PfCSP)

"We conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS against P. falciparum infection in healthy adults in Mali over a 6-month malaria season"

#Plasmodium #Malaria #MonoclonalAntibody #clinicaltrial

https://www.nejm.org/doi/full/10.1056/NEJMoa2206966?query=featured_home

Treatment Triggers Teeth to Thrive - We humans like to think we’re pretty advanced, but we can’t regrow missing teeth i... - https://hackaday.com/2021/04/13/treatment-triggers-teeth-to-thrive/ #monoclonalantibodytreatment #bonemorphogenicprotein #monoclonalantibody #toothregeneration #medicalhacks #usag-1 #teeth #news